Alessio Fiascarelli
Overview
Explore the profile of Alessio Fiascarelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zicari S, Merlino G, Paoli A, Fiascarelli A, Tunici P, Bisignano D, et al.
J Cell Mol Med
. 2024 Dec;
28(23):e70235.
PMID: 39653657
MEN1703 is a first-in-class, oral, Type I dual PIM/FMS-like tyrosine kinase 3 inhibitor (FLT3i) investigated in a Phase I/II DIAMOND-01 trial in patients with acute myeloid leukaemia (AML). Gilteritinib is...
2.
Dubash T, Bardia A, Chirn B, Reeves B, LiCausi J, Burr R, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(1):43-56.
PMID: 37318638
Purpose: Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD)...
3.
Fiascarelli A, Merlino G, Capano S, Talucci S, Bisignano D, Bressan A, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(1):13-23.
PMID: 36913051
Purpose: Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and...
4.
Tosca E, Borella E, Piana C, Bouchene S, Merlino G, Fiascarelli A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(11):1626-1639.
PMID: 36793223
MEN1611 is a novel orally bioavailable PI3K inhibitor currently in clinical development for patients with HER2-positive (HER2+) PI3KCA mutated advanced/metastatic breast cancer (BC) in combination with trastuzumab (TZB). In this...
5.
Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, et al.
Haematologica
. 2020 Nov;
105(11):2584-2591.
PMID: 33131247
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody...
6.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, et al.
Mol Cancer Ther
. 2019 Jun;
18(9):1533-1543.
PMID: 31227646
CD205 is a type I transmembrane glycoprotein and is a member of the C-type lectin receptor family. Analysis by mass spectrometry revealed that CD205 was robustly expressed and highly prevalent...
7.
Paiardini A, Tramonti A, Schirch D, Guiducci G, di Salvo M, Fiascarelli A, et al.
Biochim Biophys Acta
. 2016 Aug;
1864(11):1506-17.
PMID: 27530298
The cytosolic and mitochondrial isoforms of serine hydroxymethyltransferase (SHMT1 and SHMT2, respectively) are well-recognized targets of cancer research, since their activity is critical for purine and pyrimidine biosynthesis and because...
8.
Marani M, Paone A, Fiascarelli A, Macone A, Gargano M, Rinaldo S, et al.
Oncotarget
. 2015 Dec;
7(4):4570-83.
PMID: 26717037
Serine hydroxymethyltransferase (SHMT) is a central enzyme in the metabolic reprogramming of cancer cells, providing activated one-carbon units in the serine-glycine one-carbon metabolism. Previous studies demonstrated that the cytoplasmic isoform...
9.
Tramonti A, Fiascarelli A, Milano T, Di Salvo M, Nogues I, Pascarella S, et al.
FEBS J
. 2015 Jun;
282(15):2966-84.
PMID: 26059598
Pyridoxal 5'-phosphate (PLP), the well-known active form of vitamin B6 , is an essential enzyme cofactor involved in a large number of metabolic processes. PLP levels need to be finely...
10.
Paiardini A, Fiascarelli A, Rinaldo S, Daidone F, Giardina G, Koes D, et al.
ChemMedChem
. 2015 Feb;
10(3):490-7.
PMID: 25677305
Metabolic reprogramming of tumor cells toward serine catabolism is now recognized as a hallmark of cancer. Serine hydroxymethyltransferase (SHMT), the enzyme providing one-carbon units by converting serine and tetrahydrofolate (H4...